| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MTEM Overview
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.08 |
| 52 Week High | US$5.70 |
| 52 Week Low | US$15.19 |
| Beta | 1.15 |
| 1 Month Change | -7.03% |
| 3 Month Change | -14.25% |
| 1 Year Change | -37.96% |
| 3 Year Change | 45.11% |
| 5 Year Change | n/a |
| Change since IPO | 1.33% |
Recent News & Updates
Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts
Molecular Templates, Inc. ( NASDAQ:MTEM ) shareholders will have a reason to smile today, with the analysts making...
Shareholder Returns
| MTEM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.1% | 1.1% | 3.8% |
| 1Y | -38.0% | 17.8% | 31.5% |
Return vs Industry: MTEM underperformed the US Biotechs industry which returned 17.8% over the past year.
Return vs Market: MTEM underperformed the US Market which returned 31.5% over the past year.
Price Volatility
| MTEM volatility | |
|---|---|
| MTEM Beta | 1.15 |
| Industry Beta | 0.98 |
| Market Beta | 1 |
Stable Share Price: MTEM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MTEM's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 254 | Eric Poma | https://www.mtem.com |
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company’s lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin’s lymphoma.
Molecular Templates Fundamentals Summary
| MTEM fundamental statistics | |
|---|---|
| Market Cap | US$341.35m |
| Earnings (TTM) | -US$94.05m |
| Revenue (TTM) | US$26.15m |
13.1x
P/S Ratio-3.6x
P/E RatioIs MTEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MTEM income statement (TTM) | |
|---|---|
| Revenue | US$26.15m |
| Cost of Revenue | US$84.37m |
| Gross Profit | -US$58.22m |
| Expenses | US$35.83m |
| Earnings | -US$94.05m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.68 |
| Gross Margin | -222.64% |
| Net Profit Margin | -359.66% |
| Debt/Equity Ratio | 36.0% |
How did MTEM perform over the long term?
See historical performance and comparisonValuation
Is Molecular Templates undervalued compared to its fair value and its price relative to the market?
3.5x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MTEM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MTEM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MTEM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MTEM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTEM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MTEM is overvalued based on its PB Ratio (3.5x) compared to the US Biotechs industry average (2.9x).
Future Growth
How is Molecular Templates forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
-4.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MTEM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MTEM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MTEM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MTEM's revenue (24% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: MTEM's revenue (24% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MTEM is forecast to be unprofitable in 3 years.
Past Performance
How has Molecular Templates performed over the past 5 years?
-45.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTEM is currently unprofitable.
Growing Profit Margin: MTEM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MTEM is unprofitable, and losses have increased over the past 5 years at a rate of 45.7% per year.
Accelerating Growth: Unable to compare MTEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: MTEM has a negative Return on Equity (-96.56%), as it is currently unprofitable.
Financial Health
How is Molecular Templates's financial position?
Financial Position Analysis
Short Term Liabilities: MTEM's short term assets ($205.3M) exceed its short term liabilities ($44.7M).
Long Term Liabilities: MTEM's short term assets ($205.3M) exceed its long term liabilities ($102.7M).
Debt to Equity History and Analysis
Debt Level: MTEM's debt to equity ratio (36%) is considered satisfactory.
Reducing Debt: MTEM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTEM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MTEM has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 35.6% each year.
Dividend
What is Molecular Templates's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MTEM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MTEM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTEM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTEM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MTEM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.9yrs
Average management tenure
CEO
Eric Poma (49 yo)
12.75yrs
Tenure
US$4,609,278
Compensation
Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD4.61M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: MTEM's management team is considered experienced (3.9 years average tenure).
Board Members
Experienced Board: MTEM's board of directors are considered experienced (4.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.
Top Shareholders
Company Information
Molecular Templates, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Molecular Templates, Inc.
- Ticker: MTEM
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$341.346m
- Shares outstanding: 56.14m
- Website: https://www.mtem.com
Number of Employees
Location
- Molecular Templates, Inc.
- 9301 Amberglen Boulevard
- Suite 100
- Austin
- Texas
- 78729
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/21 23:02 |
| End of Day Share Price | 2021/10/21 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.